<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Lambert JP</dc:creator>
  <dc:creator>Picaud S</dc:creator>
  <dc:creator>Fujisawa T</dc:creator>
  <dc:creator>Hou H</dc:creator>
  <dc:creator>Savitsky P</dc:creator>
  <dc:creator>Uusküla-Reimand L</dc:creator>
  <dc:creator>Gupta GD</dc:creator>
  <dc:creator>Abdouni H</dc:creator>
  <dc:creator>Lin ZY</dc:creator>
  <dc:creator>Tucholska M</dc:creator>
  <dc:creator>Knight JDR</dc:creator>
  <dc:creator>Gonzalez-Badillo B</dc:creator>
  <dc:creator>St-Denis N</dc:creator>
  <dc:creator>Newman JA</dc:creator>
  <dc:creator>Stucki M</dc:creator>
  <dc:creator>Pelletier L</dc:creator>
  <dc:creator>Bandeira N</dc:creator>
  <dc:creator>Wilson MD</dc:creator>
  <dc:creator>Filippakopoulos P</dc:creator>
  <dc:creator>Gingras AC</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Targeting bromodomains (BRDs) of the bromo-and-extra-terminal (BET) family offers opportunities for therapeutic intervention in cancer and other diseases. Here, we profile the interactomes of BRD2, BRD3, BRD4, and BRDT following treatment with the pan-BET BRD inhibitor JQ1, revealing broad rewiring of the interaction landscape, with three distinct classes of behavior for the 603 unique interactors identified. A group of proteins associate in a JQ1-sensitive manner with BET BRDs through canonical and new binding modes, while two classes of extra-terminal (ET)-domain binding motifs mediate acetylation-independent interactions. Last, we identify an unexpected increase in several interactions following JQ1 treatment that define negative functions for BRD3 in the regulation of rRNA synthesis and potentially RNAPII-dependent gene expression that result in decreased cell proliferation. Together, our data highlight the contributions of BET protein modules to their interactomes allowing for a better understanding of pharmacological rewiring in response to JQ1.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/260575</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.molcel.2018.11.006</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30554943</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Molecular cell. - 2019</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">AP-MS</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">BET</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">JQ1</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">KacY</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">bromodomain</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">nucleolus</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">protein crystallography</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">proteomic network</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">rRNA</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">rewiring</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Antineoplastic Agents</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Azepines</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Cell Cycle Proteins</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Cell Proliferation</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Gene Expression Regulation, Neoplastic</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">HEK293 Cells</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">HeLa Cells</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">K562 Cells</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Models, Molecular</dc:subject>
  <dc:subject xmlns:ns21="xml" ns21:lang="en">Molecular Targeted Therapy</dc:subject>
  <dc:subject xmlns:ns22="xml" ns22:lang="en">Neoplasms</dc:subject>
  <dc:subject xmlns:ns23="xml" ns23:lang="en">Nuclear Proteins</dc:subject>
  <dc:subject xmlns:ns24="xml" ns24:lang="en">Protein Binding</dc:subject>
  <dc:subject xmlns:ns25="xml" ns25:lang="en">Protein Conformation</dc:subject>
  <dc:subject xmlns:ns26="xml" ns26:lang="en">Protein Interaction Domains and Motifs</dc:subject>
  <dc:subject xmlns:ns27="xml" ns27:lang="en">Protein Interaction Maps</dc:subject>
  <dc:subject xmlns:ns28="xml" ns28:lang="en">Protein-Serine-Threonine Kinases</dc:subject>
  <dc:subject xmlns:ns29="xml" ns29:lang="en">Proteomics</dc:subject>
  <dc:subject xmlns:ns30="xml" ns30:lang="en">RNA-Binding Proteins</dc:subject>
  <dc:subject xmlns:ns31="xml" ns31:lang="en">Signal Transduction</dc:subject>
  <dc:subject xmlns:ns32="xml" ns32:lang="en">Structure-Activity Relationship</dc:subject>
  <dc:subject xmlns:ns33="xml" ns33:lang="en">Transcription Factors</dc:subject>
  <dc:subject xmlns:ns34="xml" ns34:lang="en">Triazoles</dc:subject>
  <dc:title xmlns:ns35="xml" ns35:lang="en">Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
